Bringing the Best to Ohio State
Funds raised by Pelotonia have helped recruit and retain some of the brightest minds in cancer research to Ohio State. We highlight just two of the renowned senior researchers who were recruited with Pelotonia support in the past year.
Raphael E. Pollock, MD, PhD, is a globally respected cancer surgeon, researcher and educator of physicians-in-training. On Sept. 1, 2013, Pollock became a professor and director of the Division of Surgical Oncology at Ohio State, and he also serves as chief of surgical services of the OSUCCC – James. He came to Ohio State after 31 years at The University of Texas MD Anderson Cancer Center, where he played several leadership roles. Pollock’s clinical practice and laboratory research focus on soft tissue sarcoma, a rare cancer in adults but rather prevalent in children. He is principal investigator of an $11.5 million National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) grant to support collaborative sarcoma translational research. The grant is one of the largest awards ever to study sarcoma. Pollock’s SPORE research component is now located at the OSUCCC – James.
Vinay Puduvalli, MBBS, is a noted authority on developing therapies for patients with brain and spine malignancies using a combined approach of targeted therapies, innovative clinical trial designs and rational combinations of anticancer agents. Puduvalli, who serves as professor and director of the Division of Neuro-Oncology in the Department of Neurological Surgery, was recruited to Ohio State in December 2012 from MD Anderson Cancer Center, where he played several leadership roles. His research focuses on understanding the role of epigenetics in brain tumor and glioma stem cell biology, and on translating these findings to new treatment options. His lab team also works to identify mechanisms of treatment resistance, including resistance to cell death and to signaling pathway inhibitors in brain tumors. In this context, he leads several clinical trials involving epigenetic therapies and novel targeted agents.